Hexiris Ophthalmics will present first-in-human clinical results for its OBi glaucoma platform at five major ophthalmology meetings across Europe and North America this fall.

The physician-founded developer announced a program starting with the Ophthalmology Futures Forum in London on September 10, during the week of the 44th ESCRS Annual Congress. Co-founder Dr. Nir Shoham-Hazon will present the company’s clinical experience and platform details to an audience of innovators, clinicians, and investors.

Clinical Progress and Platform Design

The company’s OBi platform comprises four instruments: OBi Core, OBi Gon, OBi Shunt, and OBi Spacer. These devices are designed to span major aqueous outflow pathways, enabling glaucoma surgery to be performed at the slit lamp rather than in an operating room. This approach aims to address access bottlenecks, particularly given that a Rutgers University analysis presented at ARVO 2026 found approximately 80 percent of US counties have no glaucoma specialist.

In the first-in-human series for OBi Core, eleven eyes with mild, moderate, and advanced glaucoma were treated by three surgeons. The procedure is minimally invasive, ab externo, and transconjunctival, requiring no capital equipment. Early postoperative intraocular pressures ranged from the single digits to the low teens. No device- or procedure-related adverse events were observed during this series.

Meeting Schedule

Hexiris will participate in five key events over the coming weeks:

• Ophthalmology Futures Forum, London, September 10: Presentation of platform and first-in-human results.
• ESCRS Annual Congress, London, September 11 to 15: Presence at the 44th Congress of the European Society of Cataract and Refractive Surgeons.
• Canadian Glaucoma Society Meeting, Halifax, September 19 to 20: Hands-on OBi demonstrations for the Canadian glaucoma community.
• 57th Sally Letson Symposium, Ottawa, September 24 to 26: Hands-on OBi training for attending surgeons under the theme "Reimagining Glaucoma Care Together."
• AAO 2026, New Orleans, October 9 to 12: Showcase of the OBi platform and hands-on demonstrations at the American Academy of Ophthalmology Annual Meeting.

Commercial Outlook and Regulatory Status

These engagements precede the planned commercial introduction of OBi Core and OBi Gon in select markets in early 2027, subject to applicable regulatory requirements. Additional clinical series are being compiled, and the company’s first clinical studies are underway in Canada.

Regulatory status varies by product and jurisdiction. OBi Core holds a Health Canada medical device licence and is FDA registered. OBi Gon, OBi Shunt, and OBi Spacer are investigational and not approved for commercial use in the United States, Canada, or the European Union, except where specifically authorized.

GKB Ophthalmics shareholders unanimously approved all seven resolutions at its 44th Annual General Meeting held on August 25, 2026. The company reported that every resolution passed with 100% support from the votes polled, reflecting strong backing for the board’s governance and financial proposals.

The meeting, chaired by Chairman & Managing Director K.G. Gupta, took place at the company’s registered office in Mapusa, Goa. It commenced at 11:00 am and concluded at 11:25 am. A total of 32 shareholders were present either in person or through proxy, comprising four from the promoter group and 28 from the public category. No shareholders attended via video conferencing.

Governance Approvals

Shareholders approved the adoption of both standalone and consolidated financial statements for the fiscal year ending March 31, 2026. These ordinary resolutions received overwhelming support, with 2,202,809 votes cast in favour out of 2,202,809 polled. Institutional investors held 90,000 shares but did not cast any votes on these items.

Special resolutions were passed to re-appoint senior leadership. Mr. Cedric Lobo was re-appointed as Executive, Non-Independent, Whole Time Director, while Mr. K.G. Gupta was re-appointed as Chairman and Managing Director. Additionally, Mr. Vikram Gupta, who retires by rotation, was re-appointed as a director through an ordinary resolution. All three governance-related resolutions secured 100% approval from the votes cast.

Voting Participation Breakdown

Promoter group participation varied across resolutions. For the adoption of financial statements, promoters polled 2,155,064 votes (83.59% of their holding). However, for Mr. K.G. Gupta’s re-appointment, promoter participation dropped significantly to 650,430 votes (25.23% of holding), though those who voted did so unanimously in favour.

Public non-institutional shareholders showed consistent engagement, polling approximately 47,745 votes on most resolutions. Public institutional shareholders remained inactive throughout the meeting, casting zero votes despite holding a stake.

Operational Context

In his address, the Chairman highlighted significant global economic uncertainty affecting the manufacturing sector. He cited geopolitical tensions, changing trade policies, volatile raw material prices, and supply chain disruptions as key challenges for FY26.

Despite these headwinds, management emphasized a focus on improving operational performance and strengthening market position. The company aims to create lasting value for stakeholders amidst a complex macroeconomic environment.

Meeting Details

The company provided remote e-voting facilities from August 22 to August 24, 2026. Shareholders who did not vote remotely could cast their votes via poll at the meeting. As on the record date of August 18, 2026, the company had 2,602 shareholders.

Statutory auditors MSKA & Associates LLP, secretarial auditor Ms. Girija Nagvekar, and internal auditors RRK & Co attended the meeting. Mr. Shivaram Bhat served as the scrutinizer for the voting process. His report confirmed compliance with Section 108 of the Companies Act, 2013, and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.